Phibro Animal Health (PAHC) Stock Overview
Operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
PAHC Community Fair Values
Create NarrativeSee what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Pharmaceuticals & Biotech opportunity
LO
Fair Value from
US$7.676.1% undervalued intrinsic discount
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.
Read full narrativePhibro Animal Health Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$40.00 |
| 52 Week High | US$60.08 |
| 52 Week Low | US$22.51 |
| Beta | 0.61 |
| 1 Month Change | -30.90% |
| 3 Month Change | -22.69% |
| 1 Year Change | 63.27% |
| 3 Year Change | 177.39% |
| 5 Year Change | 42.50% |
| Change since IPO | 135.29% |
Recent News & Updates
Narrative Update • May 02
PAHC: Raised Fair Value And New Coverage Will Support Forward Repricing
Analysts have raised their fair value estimate for Phibro Animal Health by $4, from $58 to $62. This change reflects updated views on revenue growth, profit margins, and an adjusted future P/E multiple cited in recent research.
Narrative Update • Apr 18
PAHC: Future Returns Will Depend On Delivering Challenging Margin And EPS Guidance
Analysts have adjusted their price target on Phibro Animal Health to $38, reflecting updated assumptions for revenue growth, profit margin, and future P/E that they view as broadly consistent with earlier expectations. Analyst Commentary Recent research coverage on Phibro Animal Health has leaned cautious, even as the latest price target sits at $38.Recent updates
Narrative Update • May 02
PAHC: Raised Fair Value And New Coverage Will Support Forward Repricing
Analysts have raised their fair value estimate for Phibro Animal Health by $4, from $58 to $62. This change reflects updated views on revenue growth, profit margins, and an adjusted future P/E multiple cited in recent research.Narrative Update • Apr 18
PAHC: Future Returns Will Depend On Delivering Challenging Margin And EPS Guidance
Analysts have adjusted their price target on Phibro Animal Health to $38, reflecting updated assumptions for revenue growth, profit margin, and future P/E that they view as broadly consistent with earlier expectations. Analyst Commentary Recent research coverage on Phibro Animal Health has leaned cautious, even as the latest price target sits at $38.Narrative Update • Apr 03
PAHC: Future Returns Will Rely On Achieving Aggressive Margin Outlook
Narrative Update on Phibro Animal Health Analysts lifted their price target on Phibro Animal Health by $6 to $38, citing updated assumptions around the discount rate, revenue growth, profit margin, and future P/E as key drivers of the change. Analyst Commentary Recent commentary around Phibro Animal Health has been mixed, with some research pointing to upside potential and others flagging reasons to be more cautious.Narrative Update • Mar 20
PAHC: Revised Earnings Outlook And Profitability Assumptions Will Support Measured Repricing
Analysts have raised their price target on Phibro Animal Health by $8 to reflect updated assumptions around fair value, profitability, and future P/E, while also making slight adjustments to the discount rate and revenue growth expectations. Analyst Commentary Recent research points to a more constructive stance on Phibro Animal Health, with bullish analysts revisiting their assumptions on fair value, profitability, and future P/E.
Narrative Update • Mar 06
PAHC: Raised Price Outlook And Leadership Transition Will Shape Future Balanced Returns
Analysts have raised their price target on Phibro Animal Health by $4, citing updated views reflected in their latest valuation work and supporting research commentary. Analyst Commentary Analysts raising their price target on Phibro Animal Health by $4 are signaling that their updated models and research work support a higher assessment of the company than before.Narrative Update • Feb 19
PAHC: Revised Assumptions And Leadership Shift Will Shape Future Balanced Returns
Analysts have raised their price target for Phibro Animal Health from $43 to $48.50, citing slightly revised assumptions about revenue growth, profit margins and future P/E to support the higher fair value range. Analyst Commentary Recent research indicates that the new US$48.50 price target for Phibro Animal Health reflects updated assumptions around revenue growth, profit margins and the future P/E multiple.Analysis Article • Feb 07
Phibro Animal Health Corporation Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Phibro Animal Health Corporation ( NASDAQ:PAHC ) just released its latest second-quarter results and things are looking...Narrative Update • Feb 05
PAHC: Higher Fair Value And Leadership Succession Will Support Long-Term Repricing
Analysts have lifted their price target on Phibro Animal Health to US$50 from US$45, reflecting updated assumptions on discount rate, revenue growth, profit margins, and future P/E, which they view as better aligning the shares with current expectations. Analyst Commentary Bullish analysts are highlighting that the recent lift in the price target to US$50 builds on earlier optimism, including a prior move to US$45.Narrative Update • Jan 22
PAHC: Steady Outlook And Leadership Transition Will Guide Balanced Future Returns
Analysts have lifted their price target on Phibro Animal Health to US$45 from US$34, citing updated views that support a fair value of US$43 and only minor tweaks to assumptions for discount rate, revenue growth, profit margin and future P/E. Analyst Commentary Bullish Takeaways Bullish analysts see the higher US$45 price target as aligned with their updated view of fair value around US$43, which suggests they view current execution as broadly consistent with expectations.Analysis Article • Jan 08
Investors Still Waiting For A Pull Back In Phibro Animal Health Corporation (NASDAQ:PAHC)
Phibro Animal Health Corporation's ( NASDAQ:PAHC ) price-to-earnings (or "P/E") ratio of 23.6x might make it look like...Narrative Update • Jan 08
PAHC: Elevated Price Will Depend On Delivering Ambitious Margin Assumptions
Narrative Update Overview Analysts have lifted their price target on Phibro Animal Health from US$34 to US$45, citing updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E, which together support a higher valuation anchor. Analyst Commentary The move to a US$45 price target, up from US$34, is framed as a valuation update rather than a clear bullish call, with the Equal Weight rating signaling that analysts still see a balanced risk and reward profile for Phibro Animal Health at current levels.Narrative Update • Dec 21
PAHC: Clearer Earnings Trajectory Will Support Margins And Strengthen Upside Potential
Analysts have raised their price target on Phibro Animal Health to $45 from $34, reflecting increased conviction in the company's earnings trajectory and valuation resilience. Analyst Commentary Analysts describe the higher price target as a reflection of improving confidence in Phibro Animal Health's ability to deliver on earnings expectations while maintaining a resilient valuation profile relative to sector peers.Narrative Update • Dec 07
PAHC: Raised Price Outlook Will Support Margins Amid Measured Earnings Prospects
Analysts have raised their price target on Phibro Animal Health by $11 to $45, citing a more favorable outlook that is reflected in slightly improved long term growth and profitability assumptions. Analyst Commentary Bullish analysts view the higher price target as confirmation that Phibro Animal Health is executing well against its strategic plan, with improved visibility into long term revenue growth and margin expansion.Narrative Update • Nov 23
PAHC: Recent Guidance And Integration Will Support Margins Amid Normalizing Outlook
Analysts have raised their average price target for Phibro Animal Health from $39.75 to $43.00. This adjustment follows stronger projected revenue growth and margins, which have been cited after robust earnings guidance and recent industry updates.Analysis Article • Nov 08
Results: Phibro Animal Health Corporation Exceeded Expectations And The Consensus Has Updated Its Estimates
Phibro Animal Health Corporation ( NASDAQ:PAHC ) investors will be delighted, with the company turning in some strong...Narrative Update • Nov 07
PAHC: Margin Expansion And Business Integration Will Support Performance Amid Moderating Sales
Narrative Update on Phibro Animal Health Analysts have raised their price target for Phibro Animal Health by $4.00 to $39.75. This change is attributed to stronger-than-expected financial guidance, improved profit margins, and continued benefits from recent business integration initiatives.Seeking Alpha • Sep 02
Phibro Animal Health: Zoetis Growth, Valuation Still Attractive
Summary Phibro Animal Health Corporation’s Zoetis MFA acquisition has revitalized its overall growth. Animal Health is now around 75% of their total sales, and its integration should be finalized by Q4 2025. Post-integration, PAHC believes Zoetis MFAs will normalize to flat growth. But, Vaccines and Nutritional Specialties should continue growing at double digits. PAHC’s Phibro Forward initiative is also adding new efficiencies in procurement, commercial, and process improvements. Thus, PAHC believes its margins should improve through 2027. Though I also reckon there are antibiotic regulatory risks as well as potential tariff uncertainties. Still, PAHC’s valuation remains relatively cheap today. This is why I ultimately reiterate my Buy on the stock at these levels. Read the full article on Seeking AlphaNarrative Update • Aug 30
Zoetis MFA Portfolio Integration Will Expand Domestic And International Demand
Phibro Animal Health’s analyst price target has been raised to $32.50, reflecting increased confidence in above-consensus FY26 guidance, successful integration of recent acquisitions, and strengthened forward outlook, despite some concerns over the sustainability of growth. Analyst Commentary Strong initial FY26 guidance significantly above Street consensus, indicating improved profit outlook.Analysis Article • Aug 29
Phibro Animal Health Corporation's (NASDAQ:PAHC) Shares Bounce 37% But Its Business Still Trails The Industry
Phibro Animal Health Corporation ( NASDAQ:PAHC ) shares have continued their recent momentum with a 37% gain in the...Analysis Article • Aug 21
Phibro Animal Health (NASDAQ:PAHC) Has Affirmed Its Dividend Of $0.12
Phibro Animal Health Corporation's ( NASDAQ:PAHC ) investors are due to receive a payment of $0.12 per share on 24th of...Analysis Article • Aug 02
Phibro Animal Health (NASDAQ:PAHC) Has Affirmed Its Dividend Of $0.12
Phibro Animal Health Corporation ( NASDAQ:PAHC ) has announced that it will pay a dividend of $0.12 per share on the...Analysis Article • Jul 02
Phibro Animal Health (NASDAQ:PAHC) Takes On Some Risk With Its Use Of Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • May 15
Statutory Profit Doesn't Reflect How Good Phibro Animal Health's (NASDAQ:PAHC) Earnings Are
Phibro Animal Health Corporation's ( NASDAQ:PAHC ) strong earnings report was rewarded with a positive stock price...Analysis Article • May 10
Phibro Animal Health Corporation Just Recorded A 11% EPS Beat: Here's What Analysts Are Forecasting Next
Shareholders of Phibro Animal Health Corporation ( NASDAQ:PAHC ) will be pleased this week, given that the stock price...Seeking Alpha • Feb 13
Phibro Animal Health Is Cruising With Its Recent Zoetis Acquisition
Summary Phibro Animal Health delivers animal health and nutritional solutions through feed additives, vaccines, and performance products. The Zoetis acquisition added 37 product lines, driving a 24% increase in net sales and 64% growth in adjusted EBITDA. The company projects strong revenue growth in 2025 with expanding margins and updated EPS guidance. PAHC maintains diversified production in Brazil, Israel, and the U.S., minimizing tariff risks from China. My main concerns now are the relatively large debt and some cash burn. However, at a forward P/E of 12.7, I would say the current valuation seems quite cheap. Read the full article on Seeking AlphaAnalysis Article • Feb 08
Phibro Animal Health (NASDAQ:PAHC) Has Affirmed Its Dividend Of $0.12
Phibro Animal Health Corporation's ( NASDAQ:PAHC ) investors are due to receive a payment of $0.12 per share on 26th of...Analysis Article • Jan 28
Phibro Animal Health Corporation's (NASDAQ:PAHC) Popularity With Investors Is Clear
With a price-to-earnings (or "P/E") ratio of 51.9x Phibro Animal Health Corporation ( NASDAQ:PAHC ) may be sending very...Analysis Article • Nov 25
Phibro Animal Health (NASDAQ:PAHC) Is Paying Out A Dividend Of $0.12
The board of Phibro Animal Health Corporation ( NASDAQ:PAHC ) has announced that it will pay a dividend of $0.12 per...Analysis Article • Nov 13
There May Be Reason For Hope In Phibro Animal Health's (NASDAQ:PAHC) Disappointing Earnings
Phibro Animal Health Corporation's ( NASDAQ:PAHC ) stock was strong despite it releasing a soft earnings report last...
New Narrative • Sep 17
Rising Costs And Currency Risks Mar Outlook, Yet Calculated Acquisitions And Initiatives Promise Growth
Increased SG&A expenses and elevated capital expenditures risk diluting net margins and EPS, impacting overall financial performance.Analysis Article • Sep 14
Phibro Animal Health Corporation's (NASDAQ:PAHC) Shares Bounce 26% But Its Business Still Trails The Industry
The Phibro Animal Health Corporation ( NASDAQ:PAHC ) share price has done very well over the last month, posting an...Analysis Article • Aug 29
Phibro Animal Health (NASDAQ:PAHC) Has Affirmed Its Dividend Of $0.12
Phibro Animal Health Corporation ( NASDAQ:PAHC ) has announced that it will pay a dividend of $0.12 per share on the...Analysis Article • Aug 15
Phibro Animal Health (NASDAQ:PAHC) Will Pay A Dividend Of $0.12
The board of Phibro Animal Health Corporation ( NASDAQ:PAHC ) has announced that it will pay a dividend on the 25th of...Analysis Article • May 14
New Forecasts: Here's What Analysts Think The Future Holds For Phibro Animal Health Corporation (NASDAQ:PAHC)
Celebrations may be in order for Phibro Animal Health Corporation ( NASDAQ:PAHC ) shareholders, with the analysts...Analysis Article • May 11
Phibro Animal Health (NASDAQ:PAHC) Is Paying Out A Dividend Of $0.12
Phibro Animal Health Corporation ( NASDAQ:PAHC ) has announced that it will pay a dividend of $0.12 per share on the...Seeking Alpha • May 01
Phibro Animal Health: An Interesting Deal With Zoetis For A Struggling Business
Summary Phibro Animal Health has seen lackluster performance over the past decade, seeing modest sales growth and declining margins. The company recently announced a significant deal with Zoetis, acquiring their medicated feed additive product portfolio for $350 million. The deal is expected to contribute $400 million in sales and be accretive to adjusted earnings, but more details are needed to fully evaluate its impact. While the deal looks compelling, it is the lack of organic performance by Phibro itself which raises the bar here to get excited. Read the full article on Seeking AlphaAnalysis Article • Apr 30
Market Participants Recognise Phibro Animal Health Corporation's (NASDAQ:PAHC) Earnings Pushing Shares 30% Higher
Phibro Animal Health Corporation ( NASDAQ:PAHC ) shares have continued their recent momentum with a 30% gain in the...Analysis Article • Feb 10
Phibro Animal Health (NASDAQ:PAHC) Is Due To Pay A Dividend Of $0.12
The board of Phibro Animal Health Corporation ( NASDAQ:PAHC ) has announced that it will pay a dividend of $0.12 per...Analysis Article • Dec 06
Phibro Animal Health (NASDAQ:PAHC) Use Of Debt Could Be Considered Risky
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Shareholder Returns
| PAHC | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -26.8% | -1.9% | 2.2% |
| 1Y | 63.3% | 33.5% | 31.1% |
Return vs Industry: PAHC exceeded the US Pharmaceuticals industry which returned 33.5% over the past year.
Return vs Market: PAHC exceeded the US Market which returned 31.1% over the past year.
Price Volatility
| PAHC volatility | |
|---|---|
| PAHC Average Weekly Movement | 10.0% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: PAHC has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: PAHC's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1946 | 2,475 | Jack Bendheim | www.pahc.com |
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.
Phibro Animal Health Corporation Fundamentals Summary
| PAHC fundamental statistics | |
|---|---|
| Market cap | US$1.62b |
| Earnings (TTM) | US$95.23m |
| Revenue (TTM) | US$1.50b |
17.0x
P/E Ratio1.1x
P/S RatioIs PAHC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PAHC income statement (TTM) | |
|---|---|
| Revenue | US$1.50b |
| Cost of Revenue | US$1.01b |
| Gross Profit | US$488.62m |
| Other Expenses | US$393.38m |
| Earnings | US$95.23m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.35 |
| Gross Margin | 32.57% |
| Net Profit Margin | 6.35% |
| Debt/Equity Ratio | 203.6% |
How did PAHC perform over the long term?
See historical performance and comparisonDividends
1.2%
Current Dividend Yield20%
Payout RatioDoes PAHC pay a reliable dividends?
See PAHC dividend history and benchmarks| Phibro Animal Health dividend dates | |
|---|---|
| Ex Dividend Date | Jun 03 2026 |
| Dividend Pay Date | Jun 24 2026 |
| Days until Ex dividend | 22 days |
| Days until Dividend pay date | 43 days |
Does PAHC pay a reliable dividends?
See PAHC dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/11 18:49 |
| End of Day Share Price | 2026/05/08 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Phibro Animal Health Corporation is covered by 15 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Balaji Prasad | Barclays |
| Matthew Korn | Barclays |
| Douglas Tsao | Barclays |